COVID-19: US Remdecivir, selling price 250,000 yen: Zero patient burden in Japan
COVID-19:
【Washington】
Gilead Sciences:
June 29, COVID-19 therapeutic drug Remdecivir announced that the selling price for the government of developed countries is $ 2340 (250,000 yen) per person.
The Japanese government has granted special approval in May for Remdecivir as a therapeutic drug.
Remdecivir:
Gilead has provided it to the United States and Japan free of charge so far.
Japanese special approval is intended for critically ill patients who use mechanical ventilation.
Japanese Ministry of Health, Labor and Welfare:
In principle, the cost of hospitalization treatment for the new Corona in Japan is borne by the public sector.
With Remdecivir, patients will continue to bear no costs.
Gilead explained:
“We have reduced the price to an affordable level, even for developed countries with low purchasing power,” explained.
Most of the production from July to September will be supplied to the US government.
https://news.yahoo.co.jp/articles/dd7f7a9f4b95e82226e809101802152135c572d6
Gilead rises after pricing its coronavirus-fighting drug remdesivir (GILD)
Gilead Sciences
on Monday disclosed its pricing for remdesivir, its coronavirus-fighting drug.
Shares of the company jumped as much as 4% in premarket trading.
The company
will charge the US government and developed countries $390 per vial of remdesivir, or $2,340 for a five-day course using six vials of the drug.
Gilead also said that it will charge US private insurance companies $520 per vial, or $3,120 for a five-day course of the treatment.
Markets Insider